173 related articles for article (PubMed ID: 22069752)
21. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
[TBL] [Abstract][Full Text] [Related]
22. A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.
Moayeri M; Leysath CE; Tremblay JM; Vrentas C; Crown D; Leppla SH; Shoemaker CB
J Biol Chem; 2015 Mar; 290(10):6584-95. PubMed ID: 25564615
[TBL] [Abstract][Full Text] [Related]
23. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
Taft SC; Weiss AA
Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590
[TBL] [Abstract][Full Text] [Related]
24. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A
Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469
[No Abstract] [Full Text] [Related]
25. Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.
Glinert I; Bar-David E; Sittner A; Weiss S; Schlomovitz J; Ben-Shmuel A; Mechaly A; Altboum Z; Kobiler D; Levy H
Antimicrob Agents Chemother; 2016 Aug; 60(8):4878-85. PubMed ID: 27270276
[TBL] [Abstract][Full Text] [Related]
26. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
Yan M; Roehrl MH; Basar E; Wang JY
Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
[TBL] [Abstract][Full Text] [Related]
27. Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies.
Abboud N; De Jesus M; Nakouzi A; Cordero RJ; Pujato M; Fiser A; Rivera J; Casadevall A
J Biol Chem; 2009 Sep; 284(37):25077-86. PubMed ID: 19617628
[TBL] [Abstract][Full Text] [Related]
28. CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies.
Devera TS; Aye LM; Lang GA; Joshi SK; Ballard JD; Lang ML
Infect Immun; 2010 Apr; 78(4):1610-7. PubMed ID: 20123711
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.
Abboud N; Casadevall A
Clin Vaccine Immunol; 2008 Jul; 15(7):1115-23. PubMed ID: 18480236
[TBL] [Abstract][Full Text] [Related]
30. Different mechanisms of two anti-anthrax protective antigen antibodies and function comparison between them.
Xiong S; Zhou T; Zheng F; Liang X; Cao Y; Wang C; Feng Z; Tang Q; Zhu J
BMC Infect Dis; 2019 Nov; 19(1):940. PubMed ID: 31699037
[TBL] [Abstract][Full Text] [Related]
31. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages.
Mohamed N; Li J; Ferreira CS; Little SF; Friedlander AM; Spitalny GL; Casey LS
Infect Immun; 2004 Jun; 72(6):3276-83. PubMed ID: 15155630
[TBL] [Abstract][Full Text] [Related]
33. [Characteristics of the immune response to the lethal toxin of Bacillus anthracis].
Belova EV; Kolesnikov AV; Zakharova MIu; Dubileĭ SA; Diatlov IA; Shemiakin IG
Bioorg Khim; 2008; 34(5):639-44. PubMed ID: 19060938
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibody therapies against anthrax.
Chen Z; Moayeri M; Purcell R
Toxins (Basel); 2011 Aug; 3(8):1004-19. PubMed ID: 22069754
[TBL] [Abstract][Full Text] [Related]
35. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
Brenneman KE; Doganay M; Akmal A; Goldman S; Galloway DR; Mateczun AJ; Cross AS; Baillie LW
FEMS Immunol Med Microbiol; 2011 Jul; 62(2):164-72. PubMed ID: 21401726
[TBL] [Abstract][Full Text] [Related]
36. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
Dumas EK; Garman L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Choudhari S; Picking WD; James JA; Farris AD
Vaccine; 2017 Jun; 35(26):3416-3422. PubMed ID: 28504191
[TBL] [Abstract][Full Text] [Related]
37. [Monoclonal antibodies to B.anthracis protective antigen are capable to neutralize and to enhance the anthrax lethal toxin action in vitro].
Belova EV; Dubileĭ SA; Kravchenko TB; Kolesnikov AV; Zakharova MIu; Shemiakin IG
Mol Gen Mikrobiol Virusol; 2004; (3):21-6. PubMed ID: 15354937
[TBL] [Abstract][Full Text] [Related]
38. A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1.
Rivera J; Nakouzi A; Abboud N; Revskaya E; Goldman D; Collier RJ; Dadachova E; Casadevall A
Infect Immun; 2006 Jul; 74(7):4149-56. PubMed ID: 16790789
[TBL] [Abstract][Full Text] [Related]
39. Anthrax lethal toxin (LeTx) neutralization by PA domain specific antisera.
Verma M; Suryanarayana N; Tuteja U; Thavachelvam K; Rao MK; Bhargava R; Shukla S
Toxicon; 2017 Dec; 139():58-65. PubMed ID: 28919458
[TBL] [Abstract][Full Text] [Related]
40. Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor.
Thullier P; Avril A; Mathieu J; Behrens CK; Pellequer JL; Pelat T
PLoS One; 2013; 8(5):e65855. PubMed ID: 23741517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
